Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

BACKGROUND/AIMS: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the p...

詳細記述

保存先:
書誌詳細
出版年:Turk J Gastroenterol
主要な著者: Danış, Nilay, Toz, Hüseyin, Ünal, Nalan, Yılmaz, Mümtaz, Turan, İlker, Günşar, Fulya, Karasu, Zeki, Ersöz, Galip, Özkahya, Mehmet, Akarca, Ulus Salih
フォーマット: Artigo
言語:Inglês
出版事項: Turkish Society of Gastroenterology 2019
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699569/
https://ncbi.nlm.nih.gov/pubmed/31418413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.18833
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料